In the CRC study, I think the probability is high that we will have data showing a rise in PD-L1 and this will enable a good partnership, and this will be enough to make very large waves.

That said, what do those knowledgeable about the science think about the chances of success on meeting the endpoints in the CRC trial? The reason I'm wondering is because the the number of patients is relatively low and a checkpoint inhibitor (as I understand it) is not being tested directly but may be added as an option to the patient later on.

I think the chances are high for success on meeting the endpoints, since LL can do wonders on its own and in combination with standard therapy. I'm open to your thoughts, though, since I'm not an an expert on the science and realize others have far greater knowledge in this area.

Regardless, data showing a rise in PD-L1 would be a huge win.

Keep on keeping on and staying long